- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07587242
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping (SAFARI44)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study consists of a Screening Period of up to 44 Days, a Randomized 54 Week Treatment Period, a 54 Week Open Label Extension (OLE), and a Follow-Up Period of 6 weeks. Participants will be randomized to receive an intravenous infusion of either delpacibart-zotadirsen or placebo at the clinical study site every 6 weeks for a total of 9 doses. After completion of the randomized treatment period, all participants may enter the OLE portion of the study consisting of 9 doses of AOC 1044 regardless of group assignment in the randomized period. The final dose will occur at Week 102, followed by a final assessment at Week 108 and a safety follow-up visit at Week 114. An Independent Data Monitoring Committee (IDMC) comprising members independent and external to the Sponsor will review safety, tolerability, and efficacy (as needed) data of this study at regular intervals.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Avidity Bioscience, Inc., A Novartis Company
- Telefonnummer: 1-888-669-6682
- E-post: Novartis.email@novartis.com
Studieorter
-
-
New South Wales
-
Westmead, New South Wales, Australien
- Rekrytering
- The Children's Hospital at Westmead
-
-
-
-
-
Leuven, Belgien
- Rekrytering
- UZ Leuven
-
Liège, Belgien
- Rekrytering
- Centre Hospitalier Régional de la Citadelle
-
-
-
-
-
Nantes, Frankrike
- Rekrytering
- CHU de Nantes - Hotel-Dieu
-
Paris, Frankrike
- Rekrytering
- AP-HP Hospital Armand-Trousseau
-
-
-
-
-
Genova, Italien
- Rekrytering
- Istituto Giannina Gaslini
-
Milan, Italien
- Rekrytering
- Fondazione Serena ETS - Centro Clinico NeMO Milano
-
Milan, Italien
- Rekrytering
- IRCCS Ospedale San Raffaele
-
Roma, Italien
- Rekrytering
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Universitario Cattolica del Sacro Cuore
-
-
-
-
-
Leiden, Nederländerna
- Rekrytering
- Academisch Ziekenhuis Leiden
-
-
-
-
-
Barcelona, Spanien
- Rekrytering
- Hospital Sant Joan de Deu
-
Madrid, Spanien
- Rekrytering
- Hospital Universitario La Paz
-
Seville, Spanien
- Rekrytering
- Hospital Viamed Santa Angela De la Cruz - FutureMeds Spain
-
-
-
-
-
Newcastle, Storbritannien
- Rekrytering
- Royal Victoria Infirmary
-
Oxford, Storbritannien
- Rekrytering
- University of Oxford and Oxford University Hospitals NHS Foundation Trust
-
-
-
-
-
Essen, Tyskland
- Rekrytering
- Universitaetsklinikum Essen
-
Heidelberg, Tyskland
- Rekrytering
- Universitaetsklinikum Heidelberg
-
München, Tyskland
- Rekrytering
- Klinikum der Ludwig-Maximilians-Universitaet Muenchen
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Ambulatory males with clinical and genetic diagnosis of DMD
- Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping
- 7 to 16 years of age at time of consent
- TTR and NSAA assessment completed within the protocol specified parameters at Screening
- On a stable regimen of corticosteroids (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.
Key Exclusion Criteria:
- Previous treatment cell or gene therapy.
- Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).
- Lab values outside of the protocol specified range at Screening
- If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:
- Less than 1 month, for growth hormone and/or testosterone
- Less than 6 months for givinostat
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: AOC 1044
Participants will receive AOC 1044 intravenously (IV) every 6 weeks (Q6W) during the 54-week double-blind treatment period, followed by a 54-week open-label treatment period in which the same participants will continue to receive AOC 1044 IV Q6W |
AOC 1044 will be administered by intravenous (IV) infusion |
|
Placebo-jämförare: Placebo
Participants will receive placebo (saline) IV Q6W during the 54-week double-blind treatment period, followed by a 54-week open-label treatment period in which all participants will then receive AOC 1044 IV Q6W |
Placebo will be administered by intravenous (IV) infusion |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change from Baseline in Time to Rise (TTR) Velocity at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from Baseline in Creatine Kinase (CK) at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
|
|
Change from Baseline in 4-Stair Climb (4SC) Velocity at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
|
|
Change from Baseline in 10-Meter Walk/Run Test (10MWRT) Velocity at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
|
|
Change from Baseline in Stride Velocity 95th Centile (SV95C) at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
|
|
Change from Baseline in North Star Ambulatory Assessment (NSAA) Total Score at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
|
|
Change from Baseline in DMD Quality of Life (DMD-QoL) Score at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
|
|
Change from Baseline in Patient Global Impression of Severity (PGI-S) at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
|
|
Change from Baseline in Caregiver Global Impression of Severity (CaGI-S) at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
|
|
Patient Global Impression of Change (PGI-C) at Week 54
Tidsram: Week 54
|
Week 54
|
|
|
Change from Baseline in Quantitative Muscle Testing (QMT) at Week 54
Tidsram: Baseline, Week 54
|
Baseline, Week 54
|
|
|
Caregiver Global Impression of Change (CaGI-C) at Week 54
Tidsram: Week 54
|
Caregiver Global Impression of Change (CaGI-C) at Week 54 |
Week 54
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neurodegenerativa sjukdomar
- Heredodegenerativa störningar, nervsystemet
- Genetiska sjukdomar, X-länkade
- Myotoniska störningar
- Medfödda, ärftliga och neonatala sjukdomar och abnormiteter
- Genetiska sjukdomar, medfödda
- Muskeldystrofier
- Myotonisk dystrofi
- Muskelsjukdomar
- Muskeldystrofi, Duchenne
- Muskuloskeletala sjukdomar
- Sjukdomar i nervsystemet
- Neuromuskulära sjukdomar
- Spädbarn, nyfödda, sjukdomar
- Muskelstörningar, atrofisk
Andra studie-ID-nummer
- AOC 1044-CS3
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .